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ABSTRACT
Actinic keratoses (AK) are the most common
premalignant pathology seen in dermatological
practice and represent a burgeoning burden
upon health services. Increasingly recognized is
the damage to surrounding, perilesional skin,
forming the premise for field-directed therapy.
Ingenol mebutate gel is a novel agent for field-
directed treatment of AK, requiring only 2 or
3 days of application. Following an overview of
existing treatment modalities, the authors
review recent trials and safety data pertaining
to the use of ingenol mebutate gel and discuss
its role in the treatment of AK.




Actinic keratoses (AK), also known as solar
keratoses, are the most common premalignant
dermatological presentation [1, 2]. Increasing
exposure to ultraviolet (UV) rays compounded
by an aging population, has caused the
prevalence of these lesions to be increasing
worldwide, reported as being 11–25% across all
age groups [3], rising to 34% among men over
the age of 70 years [4] and 60% in those over the
age of 40 years living in Australia [5]. They are a
particular health risk in those with susceptible
Fitzpatrick skin types 1 and 2, as they will incur
enough sun exposure in normal everyday life to
cause AK [2]. Other than genetic susceptibility,
risk factors for the development of AK include
age, UV radiation, gender (with men being
more commonly affected [6]), as well as
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immunosuppression, notably in organ transplant
recipients [7, 8].
Following an overview of the treatment
modalities currently available, this review
focuses upon recent phase 3 trials of ingenol




AK has been considered by some authors to be
one end of a carcinogenesis continuum, as early
squamous cell carcinoma (SCC) in situ with the
potential to progress to invasive SCC [9–11].
Approximately 10% of patients with AK will
eventually develop invasive SCC, rising to 40%
in immunocompromised patients [12, 13].
Certain genetic conditions, including albinism
and xeroderma pigmentosum, also impart a
greater risk [14]. Furthermore, it has been
shown that the relative risk of SCC increases
with the number of AK lesions with an increase
from 1% in those with fewer than five lesions to
20% in those with more than 20 [15], thus
forming the premise for implementing field
therapy in the treatment of multiple AK [6, 16].
METHODS
The authors performed a specific search on
MEDLINE, using search terms ‘‘PEP005,’’
‘‘ingenol mebutate,’’ and ‘‘ingenol-3-angelate.’’
Additional sources of evidence included
systematic reviews on AK published since
2000, identified on MEDLINE using the term
‘‘actinic keratosis,’’ ‘‘actinic keratoses,’’ ‘‘solar
keratosis,’’ and ‘‘solar keratoses.’’ The authors




Uncertainty persists as to whether AK should be
treated and if so, their optimal management.
The 2007 British Association of Dermatologists
(BAD) guidelines recommend that, if there is
little concern and the patient is not troubled by
the lesion, no medical treatment is necessary
[8]. This is based on evidence by Harvey et al.
showing that 21% of AK resolved spontaneously
over a 12-month period. Additionally, there is a
low rate of malignant transformation, with less
than one in 1,000 per annum reported in some
studies [6, 16, 17].
There are several options available for the
treatment of AK. There is some evidence that
the application of sun block twice daily for
7 months is desirable as a preventative measure
for the development of AK [18]. Similar daily
application has also demonstrated a reduced
incidence of SCC [15]. Emollient use alone is
also a reasonable treatment option though it is
likely to be managing the clinical symptoms of
mild AK rather than reversing any molecular
process. The results supporting its use come
from the placebo arm of trials assessing other
treatments. When hyaluronan was used as a
placebo vehicle in a randomized study to
compare diclofenac gel, there was resolution
of lesions in 44% of participants after 60 days
[19]. Comparatively, diclofenac gel resolved
70% of lesions [19].
The most widely used management option
for small, isolated lesions is cryotherapy with
liquid nitrogen. Evidence supporting its use
comes from a randomized study comparing
cryotherapy with photodynamic therapy
(PDT); after 3 months, complete response was
seen in 73% after two cycles of cryotherapy
(one session) compared with 69% after a
single session of PDT [20]. Cryotherapy can
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be associated with pain during application
and postprocedural blistering and
hypopigmentation.
The use of topical therapies, while effective,
is often limited by the protracted course of
treatment required and local side effects, which
are often not tolerated by patients. One of the
most widely recognized of these is 5-fluorouracil
(5-FU), a topical chemotherapeutic agent,
which works by inhibiting thymidylate
synthetase hence disrupting DNA synthesis.
When used twice daily for 3 weeks, 5-FU is
associated with reduction of lesional area by
70% [21]. This regimen can result in skin
irritation, dryness, erythema, and exfoliation,
and thus less aggressive schedules are often
used, but their efficacy remains to be fully
evaluated.
Imiquimod cream 5% is an immune
response modifier that acts via stimulation of a
toll-like receptor. Randomized controlled trials
have demonstrated its efficacy both clinically
and histologically over a 16-week treatment
course [22, 23]. Complete clinical clearance was
achieved in 47% of patients and partial in 64%.
It is more expensive, gram for gram, than 5-FU
with a similar side effect profile, including
severe erythema as well as scabbing and
crusting (30%) with some ulceration (10%) [8].
Current dosage recommendations are three
times weekly for 4 weeks, evaluating response
to treatment after a further 4 weeks, notably a
shorter observation period than for other
treatments.
FIELD-DIRECTED THERAPY
AK are rarely solitary lesions. The idea of field
change was first described in 1953, and more
recently, this concept has been demonstrated at
molecular level. Patches of genetically altered
stem cell clones develop into individual fields
that eventually mature into contiguous pastures
of precancerous cells [24]. This mandates field
therapy rather than targeting individual lesions.
Further support for this management concept
comes from data showing 82% of SCCs arise
within, in close proximity to, or in a region
contiguous with AK. Furthermore, it is
acknowledged that the risk of surrounding
skin to develop SCC is reduced if AK lesions
are treated [25].
Cryotherapy can be used in a field-directed
manner, in which it is referred to as
cryopeeling. Chiarello [26] demonstrated good
clinical outcome with a low recurrence rate as
well as a lower subsequent incidence of SCC.
However, owing to its side effect profile, this
treatment modality is rarely used in normal
clinical practice.
PDT is particularly useful when lesions are
numerous as well as when they are located in
areas of poor wound healing [8, 27]. PDT
marries the use of a photosensitizing drug
with targeted phototherapy to act on rapidly
dividing atypical keratinocytes with treatment
rates of about 90% reported [20, 28, 29]. In a
randomized intraindividual study, Morton et al.
compared PDT with double freeze–thaw
cryotherapy, repeating treatments at 3 months
if required. After 24 weeks both groups had
similarly high response rates (PDT 89.1% and
cryotherapy 86.1%) but cosmetic outcome and
satisfaction was consistently rated significantly
higher in the PDT group [30]. This treatment
option is, however, limited by the need for a
costly dedicated light source, the application of
a photosensitizing cream as well as local pain
both during and after treatment associated with
photosensitivity, which all have an impact on
patient compliance.
As newer evidence becomes available, more
experts are advocating the early treatment of AK
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to reduce the potential risk of it progressing
to malignant disease. While there is no
chemopreventive approach to eliminate
progression to nonmelanoma skin cancer, the
various aforementioned treatment options show
benefit in terms of skin cancer prophylaxis
and extending the time to its development
[31]. Problems in the implementation of field-
directed therapy include the requirement for
adequate volumes of medication (where
applicable) and provocation of a wide area of
long-lived, inflammatory change and associated
discomfort.
INGENOL MEBUTATE
Since 1917, the sap of Euphorbia peplus,
commonly referred to as petty spurge in the
United Kingdom or radium weed in Australia,
has been used as a home treatment for
dermatological malignancies, including AK and
basal cell carcinomas [32–34]. The active
ingredient of E. peplus, has since been
identified as ingenol mebutate (ingenol-3-
angelate, previously PEP005), a hydrophobic,
macrocyclic diterpene ester [35–37], which was
licensed for use in AK by the US Food and Drug
Association (FDA) in January 2012.
Ingenol mebutol is believed to have a dual
mode of action via both cellular necrosis and
neutrophil-mediated, antibody-dependent
cellular cytotoxicity [38]. First, exposure of
cancerous cells to ingenol mebutate induces
mitochondrial depolarization, facilitating
intracellular calcium release, disruption of
cytoplasmic organelles, and eventual cellular
necrosis within 1–2 h of application [35].
Secondly, ingenol mubetate is believed to
cause increased production of antibodies
directed against the tumor by the humoral
immune system. The cytokine and chemokine
release that follows ingenol-mebutate-mediated
cellular necrosis induces neutrophil
recruitment, and subsequent ‘‘anti-tumor’’
antibody-dependent cellular cytotoxicity
ensues [38, 39]. Similar histological
appearances are seen on normal as on sun-
damaged murine skin following ingenol
mebutate application, albeit to a much lesser
degree [40]. The combined clinical consequence
is the expeditious, targeted elimination of
dysplastic cells following a short duration of
ingenol mebutate application.
Preliminary data from animal models,
suggested efficacy of topical ingenol mebutate
against human SCC, cervical carcinoma, and
melanoma xenografts implanted into murine
recipients [35].
Initial phase 1/2 studies trialled E. peplus sap
in 36 patients (48 lesions) who had refused,
failed, or were not suitable for conventional
medical or surgical therapy for nonmelanoma
skin cancer, thus deemed ‘‘relatively
unfavorable.’’ Complete clinical response rate
at 1 month was 82% for basal cell carcinoma,
94% for carcinoma in situ, and 75% for SCC; for
superficial (\16 mm) carcinoma in situ, the
corresponding response rate was 100% [41].
The initial human phase 1 study of ingenol
mebutate, which utilized a single topical
application of 0.01% concentration, showed
increased clearance compared with vehicle
control and a sound safety profile [42].
Phase 2 dose-escalation studies showed a
dose–response effect and concluded that
appropriate dosage of ingenol mebutate on the
trunk and extremities is 0.05% concentration
gel on two consecutive days [36] with higher
concentrations (such as 0.075%) predisposing
to dose-limiting toxicity, comprising severe
crusting and flaking. On the face and scalp,
0.015% concentration gel on three consecutive
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days has been used as the maximally efficacious
dose with minimal side effects [43].
Two phase 3 randomized studies compared
ingenol mebutate gel 0.05% applied on two
consecutive days versus vehicle application to a
25 cm2 contiguous field on AK on the trunk and
limbs. Pooled analysis of both trials included
458 patients. In ingenol mebutate versus vehicle
groups, individuals showed 34.1% versus 4.7%
complete clearance, 49.1% versus 6.9% partial
clearance (defined as [75% reduction) and
median reduction in the number of AK of 75%
versus 0% [43]. Concurrently, two phase 3 trials
compared 3 days of 25 cm2 field-directed
application of ingenol mebutate gel 0.025% to
the face and scalp versus vehicle control. In the
pooled analysis of 547 patients, complete
clearance was achieved in 42.2% ingenol
mebutate subjects versus 3.7% vehicle control,
partial clearance ([75% reduction) in 63.9%
versus 7.4% and corresponding median
reduction in number of AK of 83% versus 0%.
Long-term follow-up of patients who had
achieved clinical clearance in these phase 3
trials showed that 44.0% of patients with AK on
trunk and limbs and 46.1% with AK on face and
scalp sustained their clearance after 12 months,
with a reduction in AK numbers of 86.8 and
87.2%, respectively [43].
Together, these results suggest that 2 days
field-directed application of ingenol mebutate
0.05% on the trunk and extremities, or 3 days
field-directed application of ingenol mebutate
0.015%, is significantly more efficacious than
vehicle control with respect to complete and
partial clearance of lesions, ingenol mebutate is
well tolerated and its therapeutic effect long-
lived.
The most consistently reported side effects of
ingenol mebutate are erythema, flakiness,
crusting, pruritus, and pain, experienced by up
to 97.5% patients, with effects peaking between
days 3 and 8 and mostly resolved by day 15 [43].
A favorable safety profile has been consistently
reported with no detectable systemic absorption
[44]; long-term (12 months) follow-up data
showed no treatment-related serious adverse
events or deaths [43]. Complete clearance rates
are comparable with clinical trials of diclofenac
applied for up to 90 days, imiquimod applied
for 16 weeks, and 5-FU applied for 4 weeks.
INGENOL MEBUTATE: FUTURE
ROLE IN THERAPY
AK represents the most common dermatological
premalignant pathology, whose incidence
will inevitably increase in the upcoming
decades, imposing an increasing burden on our
healthcare systems. The use of current
treatments, while effective, may be limited by
patient tolerance of the protracted courses of
treatment required, compliance with therapy
and access to secondary care resources (such
as phototherapy suites). Ingenol mebutate
represents a promising therapy for AK on both
facial and extra-facial sites. Requiring only two
applications, ingenol mebutate will be of
particular value for patients unable to tolerate
the side effects endured during a protracted
course of treatment with 5-FU or imiquimod
and is well suited to patients with AK on sites
notorious for poor healing, such as the lower
legs. Furthermore, adherence to prescribed
therapy is likely to be greater with ingenol
mebutate particularly for those patients who,
for reasons of dependence, rely upon carers or
relatives to assist them with their treatment.
With increasing use, more comprehensive
medicine information relating to ingenol
mebutate will follow, including data relating to
application over larger areas and in combination
with other agents, and randomized trials more
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conclusively comparing ingenol mebutate with
its competitors will ensue.
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